Dr. Heidi Noels and Dr. Yvonne Döring receive the W.H. Hauss Award from the DGAF
19-21 April 2018
Dr. Heidi Noels from the Institute for Molecular Cardiovascular Research at RWTH Aachen University together with Dr. Yvonne Döring from the Institute for Prophylaxis and Epidemiology of Circulatory Diseases at LMU Munich together received the DGAF W.H. Hauss Award 2018 from the German Society for Atherosclerosis Research (DGAF) during the 32nd Annual Meeting of the DGAF in Rauischholzhausen, Germany. They were awarded for their publication "Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies." (Circulation. 2017; 136: 388-403). In this work it could be shown that vascular CXCR4 has an atheroprotective function by maintaining the arterial integrity and preserving the endothelial barrier function. In addition, CXCR4 stabilizes a contractile smooth muscle cell phenotype. Targeted enhancement of these CXCR4-mediated protective functions could open up novel therapeutic options in the treatment of atherosclerosis.
The award was sponsored by a long-standing active member of the DGAF, Prof. Dr. Winfried März.
Project area Z
Administrative project
Robert Werner Mertens
MD student
University Hospital RWTH Aachen
Department of Internal Medicine
Project: The role of incretin hormone GLP-2 in septic cardiomyopathy
PI: Michael Lehrke
Robert Werner Mertens
MD student
University Hospital RWTH Aachen
Department of Internal Medicine
Project: The role of incretin hormone GLP-2 in septic cardiomyopathy
PI: Michael Lehrke
Consortium
Mechanisms of Cardiovascular Complications
in Chronic Kidney Disease
The SFB/TRR219 is supported by the German Research Foundation (DFG)
Project-ID 322900939
Welcome in SFB Evaluation
Welcome to SFB Evaluation
Vorantrag/Pre-application
Publications within pre-application:
accepted but not yet online available in revision or submitted
C-01 Floege
Terhuerne J, van Diepen M, Kramann R, Erpenbeck J, Dekker F, Marx N, Floege J, Schlieper G. Speckle tracking Echocardiography for prediction of cardiovascular mortality in patients with End Stage Renal Disease. Clin Kidney J (Accepted).
C-04 Jankowski J
Orth-Alampour S, Gayrard N, Salem S, Bhargava S, Jankowski V, Jover, Notarnicola C, Noels H, P.C. van der Vorst E, Theelen W, Bruck H, Fliser D, Loscalzo J, Wu Z, Marx N; Zidek W, Argiles A, Jankowski J.
Inhibition of osteogenic transdifferentiation by an endogenous mediator for the prevention of vascular calcification.
Eur Heart J (in revision). Read
Jankowski J, Floege J., Fliser D, Böhm M., Marx N.
Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options Circulation 2021 (Accepted). Read
Noels H, Lehrke M, Vanholder R, Jankowski J.
Lipoproteins and fatty acids in CKD: from molecular and meta-bolic alterations to pathophysiology and risk for kidney and heart. Nature review nephrology (Accepted). Read
R. Vanholder , A. Argiles, J Jankowski for the European Uremic Toxin Work Group (EUTox)
A history of uremic toxicity and of the European Uremic Toxin Work Group (EUTox) Read
C-06 Van der Vorst/Kahles
Kahles F, Mertens RW, Rückbeil MV, Arrivas MC, van der Vorst EPC, Moellmann J, Lebherz C, Biener M, Giannitsis E, Katus HA, Marx N, Lehrke M.
The gut hormone GLP-2 is associated with cardiovascular risk in patients with myocardial infarction. (in preparation). Read
Sundararaman SS, Peters LJ, Jansen Y, Gencer S, Yan Y, Nazir S, Bonnin- Marquez A, Kahles F, Lehrke M, Biessen EA, Jankowski J, Weber C, Döring Y, Van der Vorst EPC. Adipocyte Calcium Sensing Receptor is not involved in in-vivo visceral adipose tissue inflammation or atherosclerosis development in hyperlipidemic Apoe-/- mice. Scientific Reports. (in revision). Read
C-08 Speer
Schunk SJ; Ampofo E, Triem S, Sarakpi T, Becker E, Hütter G, Hohl M, Alansary D, Prates-Roma L, Lipp P, Möllmann J, Lehrke M, Laschke MW, Menger MD, Kramann R, Boor P, Göttsch C, Laufs U, Marx N, Niemeyer BA, Fliser D, Speer T. T Interleukin-1 a is a central regulator of inflammation in cardiovascular and kidney diseases. (in revision). Read
Schunk SJ, Beisswenger C, Ritzmann F, Herr C, Wagner M, Triem S, Hütter G, Schmit D, Zewinger S, Sarakpi T, Honecker A, Boor P, Jörres R, Watz H, Welte T, Vogelmeier CF, Fliser D, Bals R, Speer T. Urinary Dickkopf-3 (DKK3) uncovers inapparent progressive kidney injury: an observational study and experimental validation. (in revision). Read
Schunk SJ, Hermann J, Triem S, Sarakpi T, Lellig M, Hahm E, Zewinger S, Möllmann J, Lehrke M, Kramann R, Boor B, Lipp P, Laufs U, Reiser J, Jankowski J, Fliser D, Speer T, Jankowski V. Guanidinylated apolipoprotein C3 (ApoC3) causes cardiovascular and kidney injury. (in revision). Read
C-09 Schunk/Fliser
Schunk SJ, Kleber MK, März W, Pang S, Zewinger S, Triem S, Ege P, Reichert MC, Krawczyk K, Weber SN, Jaumann I, Schmit D, Sarakpi T, Wagenpfeil S, Kramann R, Boerwinkle E, Ballantyne CM, Grove-Gaona ML, Tragante V, Pilbrow AP, Richards AM, Cameron VA, Doughty RN, Dubé MP, Tardif JC, Feroz-Zada Y, Sun M, Liu C, Ko YA, Quyyumi AA, Hartiala JA, Tang WHW, Hazen SL, Allayee HA, McDonough CW, Gong Y, Cooper-DeHoff RM, Johnson JA, Scholz M, Teren A, Burkhardt R, Martinsson A, Smith JG, Wallentin L, James AK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Campbell H, eQTLGen consortium, BIOS consortium, Tierling S, Walter J, Ampofo E, Niemeyer BA, Lipp P, Schunkert H, Böhm M, Lammert L, Koenig W, Fliser D, Laufs U, Speer T. Genetically-determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. (Accepted). Read
M-02 Hohl/Böhm
Selejan SR, Linz D, Hohl M, Tatu AM, Markwirth P, Speer T, Jankowski J, Kazakov A, Werner C, Mahfoud F, Böhm M. Renal denervation improves renal remodelling and function in a model for hypertension and metabolic syndrome - role of RAGE/sRAGE balance. (Submitted). Read
Selejan SR, Linz D, Hohl M, Huynh AKD, Mautz M, Wintrich J, Kazakov A, Werner C, Mahfoud F, Böhm M. Renal denervation reduces atrial remodeling in hypertensive rats with metabolic syndrome. (Submitted). Read
Selejan SR, Linz D, Hohl M, Dederer J, Kazakov A, Zamyatkin O, Lauder L, Speer T, Krawczyk M, Lammert F, Mahfoud F, Böhm M. Effects of sympathetic modulation by renal denervation on hepatosteatosis and liver RAGE/sRAGE balance. (Submitted). Read
Selejan SR, Khoshkish S, Zamyatkin O, Hohl M, Kazakov A, Ewen S, Bachelier K, Klingel K, Wagenpfeil S, Böhm M, Kindermann I. Differentiation of inflammatory cardiomyopathy from non-inflammatory cardiomyopathy by circulating High Mobility Group Box 1 protein. (Submitted). Read
M-03 Lehrke/Marx
Marx N, Floege J. Dapagliflozin, advanced chronic kidney disease and mortality: new insights from the DAPA-CKD trial. Eur Heart J. 2021; (in press). Read
M-04 Roma/Niemeyer/Speer
Ramesh G, Jarzembowski L, Schwarz Y, Konrad M, Poth V, Schwär G, Lauer AA, Grimm MOW, Alansary D, Bruns D, Niemeyer BA: Short STIM1B uncovers a mechanism of synaptic enhancement. Cell Reports 2021. (Accepted). Read
Schunk SJ, Kleber MK, März W, Pang S, Zewinger S, Triem S, Ege P, Reichert MC, Krawczyk K, Weber SN, Jaumann I, Schmit D, Sarakpi T, Wagenpfeil S, Kramann R, Boerwinkle E, Ballantyne CM, Grove-Gaona ML, Tragante V, Pilbrow AP, Richards AM, Cameron VA, Doughty RN, Dubé MP, Tardif JC, Feroz-Zada Y, Sun M, Liu C, Ko YA, Quyyumi AA, Hartiala JA, Tang WHW, Hazen SL, Allayee HA, McDonough CW, Gong Y, Cooper-DeHoff RM, Johnson JA, Scholz M, Teren A, Burkhardt R, Martinsson A, Smith JG, Wallentin L, James AK, Eriksson N, White H, Held C, Waterworth D, Trompet S, Jukema JW, Ford I, Stott DJ, Sattar N, Cresci S, Spertus JA, Campbell H, eQTLGen consortium, BIOS consortium, Tierling S, Walter J, Ampofo E, Niemeyer BA, Lipp P, Schunkert H, Böhm M, Lammert L, Koenig W, Fliser D, Laufs U, Speer T. Genetically-determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. 2021. (Accepted). Read
M-05 Noels/Marx
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 2021. (Accepted). Read
Noels H, Lehrke M, Vanholder R., Jankowski J. Lipoproteins and fatty acids in CKD: from molecular and metabolic alterations to pathophysiology and risk for kidney and heart. Nature Nephrology Reviews 2021. (Accepted). Read
M-06 Werner
Selejan SR, Linz D, Hohl M, Tatu AM, Markwirth P, Speer T, Jankowski J, Kazakov A, Werner C, Mahfoud F, Böhm M. Renal denervation improves renal remodelling and function in a model for hypertension and metabolic syndrome-role of RAGE/sRAGE balance. Kidney International (submitted). Read
Selejan SR, Linz D, Hohl M, Huynh D, Mauz M, Wintrich J, Kazakov A, Werner C, Mahfoud F, Böhm M. Renal denervation reduces atrial remodelling in hypertensive rats with metabolic syndrome. Basic Research in Cardiology (submitted). Read
S-03 Jankowski V/Jankowski J
Jankowski J., Floege J., Fliser D, Böhm M., Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options Circulation 2021 (Accepted). Read
Noels H, Lehrke M, Vanholder R, Jankowski J. Lipoproteins and fatty acids in CKD: from molecular and meta-bolic alterations to pathophysiology and risk for kidney and heart. Nature review nephrology (Accepted). Read
Wu Z, van der Vorst EPC, Jankowski V*, Jankowski J*. Irreversible post-translational modifications: Cardiovascular risk factors and avenue for therapy. Trend in Molecular Medicine *shared last authorship (Submitted). Read
.